Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVA-BN-RSV human RSV challenge phase 2a trial
2017-004582-27Phase 2Completed
- Sponsor
- Bavarian Nordic
- Start
- Apr 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV), upper respiratory infection (URI) and pulmonary infection comparing MVA-BN-RSV with Placebo (2 arms). Primary endpoint: RSV RNA viral load AUC by qRT-PCR. Started Apr 2018; status: completed.
02
Drugs
MVA-BN-RSV
03
Conditions
respiratory syncytial virus disease (RSV)upper respiratory infection (URI)pulmonary infection
Beyond the preview
Go deeper on 2017-004582-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004582-27.